title: Clinical outcome of cotransplantation of peripheral nerve and adrenal medulla in patients with Parkinson's disease. Clínica Puerta de Hierro Neural Transplantation Group.
abstract: OBJECTIVE
  Transplants of adrenal medulla (AM) and fetal ventral mesencephalon (FVM) are currently being tested as therapeutic alternatives in patients with Parkinson's disease (PD). At the Clínica Puerta de Hierro in Madrid, a controlled clinical trial is underway to establish which donor tissue, if any, is the best for open surgical implantation in patients with PD.
  
  
  METHODS
  Since 1987, varying degrees of clinical improvement have been achieved in Grade IV and V parkinsonian patients by implanting perfused AM and FVM into the right caudate nucleus. To investigate further whether implantation of different types of donor tissues results in qualitatively and quantitatively different degrees of recovery, four patients with Grade IV or V PD received implants of pre-coincubated autologous AM and intercostal nerve in the caudate nucleus. Four nonsurgically treated patients served as a control group. Three years posttransplantation, longer on phases (46.2%+/-10.4% of the day presurgery to 87.5%+/-10.4% of the day 36 months postsurgery) and improved symptoms in on and off phases persist in all four cases, with reduced dyskinesias (67.1%+/-9.2% of the day in on phases presurgery to 17%+/-13.8% of the day in on phases 36 months postsurgery). Progress appears to be stepwise, starting within weeks of tranplantation and becoming clinically significant in the 2nd and 3rd months (similar to our AM- and sooner than in our FVM-implanted patients), followed by a period of stability and, after a second wave of improvement 12 to 18 months posttransplantation (similar to FVM implants), has continued (87.5+/-7 points presurgery to 46+/-5.6 points 36 months postsurgery). In the experimental group, doses of levodopa have been reduced by more than 60% and dopamine agonist use has not resumed. In contrast, there have been no significant clinical changes in the control group.
  
  
  CONCLUSIONS
  Implantation of tissue other than fetal tissue can promote a long-term improvement in the clinical symptomatology of seriously disabled parkinsonian patients. This finding is supported by the autopsy report of a patient with PD who had undergone grafting of AM plus peripheral nerve in which it was demonstrated that a large number of tyrosine hydroxylase-positive cells survive 1 year after implantation. In addition, there was a dense network of host dopaminergic fibers around the graft.
authors.affiliation: Department of Neurology, Clínica Puerta de Hierro, Madrid, Spain.
authors.forename: J J
authors.initials: JJ
authors.lastname: López-Lozano
authors.forename: G
authors.initials: G
authors.lastname: Bravo
authors.forename: J
authors.initials: J
authors.lastname: Abascal
authors.forename: B
authors.initials: B
authors.lastname: Brera
authors.forename: I
authors.initials: I
authors.lastname: Millan
mesh_terms: D000313:Adrenal Medulla / Q000637:transplantation*; D000368:Aged; D002421:Caudate Nucleus / Q000601:surgery*; D006801:Humans; D007367:Intercostal Nerves / Q000637:transplantation*; D008875:Middle Aged; D010300:Parkinson Disease / Q000601:surgery*; D011183:Postoperative Complications; D011597:Psychomotor Performance